RNA-protein interaction is crucial to the functioning of the organism

In a living organism, the binding or interaction between proteins and RNA molecules is essential to the functioning of each cell and the organism as a whole. These RNA- protein interactions regulate the expression of our genes, and can be the cause of serious pathologies such as neurodegenerative diseases and cancers.

Yet these interactions are complex and difficult to explore using conventional methods. Qubit Pharmaceuticals' simulation technology promises to shine a brighter light on them. Focusing on RNA as a therapeutic target therefore opens up a whole new field of possibilities for more effective treatments, particularly for cancers that are resistant to existing treatments.

A virtually untapped research avenue

RNA-protein interactions (RPI) offer great potential as targets for the development of new therapeutic molecules. Targeting these interactions with small molecule inhibitors remains an emerging field. This project will focus on inhibiting or reducing translational activity in cancer cells by targeting RNA-protein interactions. This approach will use two different strategies:
(a) RNA targeting
(b) targeting proteins at the RNA-binding interface.

While protein-protein interactions have served as the basis for the development of new drugs, RNA-protein interactions, equally crucial in human pathologies, remain largely unexploited.

These interactions, when dysregulated, can lead to a range of human diseases. Targeting these interactions, closely implicated in pathological mechanisms, represents a promising strategy for discovering new categories of drug candidates.

Qubit Pharmaceuticals can count on its core competencies to meet this challenge. The project's scientific manager at the company, Krystel El Hage, is an expert in targeting RNA-protein interactions using computational approaches as well as spectroscopic and cellular techniques, particularly those involved in certain cancers and neurodegenerative diseases. A former leader of the European MITiC project (Molecules Inhibiting Translation in Cancer cells - European Union Horizon 2020 research and innovation program under Marie Skodowska-Curie grant agreement No. 895024), she is also known for her scientific publications on this subject in leading international journals. Today, she is pursuing this research activity within Qubit Pharmaceuticals through work aimed at revealing at atomic level the mechanisms of action involved, in order to design innovative inhibitor molecules.

New project for Qubit Pharmaceuticals' Atlas platform

Qubit Pharmaceuticals will run this project on its Atlas platform, which integrates advanced supercomputer simulation techniques with optimized small molecule identification strategies. This platform enables a precise description of the biophysical properties governing interactions between a target and a potential drug candidate.

Atlas is able to harness the computing power of supercomputers and quantum computers to accelerate the development of safer, more effective drug candidates, cutting the time needed to screen, select and optimize a candidate of interest by a factor of 2, and the investment required by a factor of more than 10. Qubit is thus able to model and simulate the interactions between molecules and macromolecules with the utmost precision. By creating true digital twins of physical molecules, the Atlas platform performs in just a few hours calculations that would take several years by conventional means - an acceleration of a factor of 100,000.

Robert Marino , CEO of Qubit Pharmaceuticals, comments: "I would like to thank Bpifrance, the Programme d'Investissement d'Avenir and France 2030 for once again showing their confidence in us. Qubit Pharma is ideally positioned to make progress in understanding and treating RNA-protein interactions, and this grant, by supporting
the creation of a new platform, will enable us to expand research and accelerate the development of innovative treatments. We are determined to demonstrate that it is possible to target RNA and RNA-protein interactions as we move from target identification to lead identification."

About Qubit Pharmaceuticals

Qubit Pharmaceuticals was founded in 2020 with the vision of co-developing new, more effective and safer drugs with pharmaceutical and biotech companies. A spin- off of the research work of five internationally renowned scientists - Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne University and CNRS), Jay Ponder (Washington University in St Louis), Pengyu Ren (University of Texas at Austin) - Qubit Pharmaceuticals leverages its Atlas
platform to discover new drugs through simulation and molecular modeling accelerated by hybrid HPC and quantum computing. The multidisciplinary team, led by CEO Robert Marino, and the founders are based in France at the Paris Santé Cochin incubator and in the USA in Boston.

About BpiFrance

Bpifrance finances companies - at every stage of their development - with loans, guarantees and equity capital. Bpifrance supports them in their innovation and expansion efforts. Bpifrance now also covers their export activities through a wide range of products. Consulting, university, networking and acceleration programs for startups, SMEs and ETIs are also part of the offer available to entrepreneurs. Thanks to Bpifrance and its 50 regional offices, entrepreneurs benefit from a close, single and efficient contact to help them face their challenges.
For more information: www.bpifrance.fr - Follow us on Twitter : @Bpifrance - @BpifrancePresse

Media contacts

Qubit Pharmaceuticals

Bruno Arabian – barabian@ulysse-communication.com – +33 6.87.88.47.26
Nicolas Daniels – ndaniels@ulysse-communication.com - + 33 6.63.66.59.22